Meliodays Medical announces the closing of a pre-seed financing round of €800k

Meliodays Medical, a pharmaceutical company developing a local, hormone-free treatment for menstrual pain, has successfully closed an oversubscribed pre-seed financing round of over €800,000. The round was led by capacura GmbH, with participation from FS Life Science Investment GmbH and several early-stage investors and business angels specializing in healthcare.

Simone Sabbione, co-founder and CEO of Meliodays Medical, stated: “We are pleased to welcome experienced healthcare and impact investors to our shareholder group. The strong interest in this round highlights the increasing awareness of menstrual pain as a serious health issue affecting a large number of people globally. This funding allows us to move forward with developing much-needed new solutions.”

Up to 80% of menstruating individuals experience period pain, and for 20–30%, the intensity can interfere with daily activities such as school, work, or social engagement. Current treatment options, including hormonal therapies and high-dose painkillers, often come with systemic side effects.

Meliodays Medical is developing MelioOne, a novel, locally acting, hormone-free therapy that delivers a small amount of pain medication directly to the uterus using a proven polymer technology. This approach aims to reduce systemic exposure while effectively targeting period pain. The funds raised will be used to further develop MelioOne and to complete preparations for preclinical development of the company’s intrauterine application. Patent protection has already been secured in over 150 countries.

Meliodays Medical is also an alum of the Summer School for Diverse Startups, a program designed to support early-stage teams led by founders from underrepresented backgrounds. The program provides access to resources, mentorship, and networks to strengthen diversity and inclusion in the startup ecosystem. Follow us on LinkedIn to not miss the new application deadline.